Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isoproterenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 1.00 |
| ▸ | ADRB3 known ✓ | P13945 | 5/20 | 0.97 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | BLM | P54132 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.97 |
| ▸ | MTOR | P42345 | 3/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoproterenol SCHEMBL9614622 | 1.00 | MAPT (1.00) | MAPTADRB2KDM4ETDP1ADRB1 | |
| Isoproterenol SCHEMBL28872988 | 1.00 | MAPT (1.00) | MAPTADRB2KDM4ETDP1ADRB1 | |
| Levisoprenaline SCHEMBL4745572 | 1.00 | MAPT (1.00) | MAPTADRB2KDM4ETDP1ADRB1 | |
| Isoproterenol SCHEMBL7627 | 1.00 | MAPT (1.00) | MAPTADRB2KDM4ETDP1ADRB1 | |
| Isoproterenol SCHEMBL4166 | 0.98 | MAPT (1.00) | MAPTADRB2KDM4ETDP1ADRB1 | |
| Isoproterenol SCHEMBL3253794 | 0.98 | MAPT (1.00) | MAPTADRB2KDM4ETDP1ADRB1 | |
| Isoproterenol SCHEMBL29386243 | 0.98 | MAPT (1.00) | MAPTADRB2KDM4ETDP1ADRB1 | |
| Isoproterenol SCHEMBL4165 | 0.98 | MAPT (1.00) | MAPTADRB2KDM4ETDP1ADRB1 | |
| Levisoprenaline SCHEMBL250806 | 0.98 | MAPT (1.00) | MAPTADRB2KDM4ETDP1ADRB1 | |
| Isoproterenol SCHEMBL29519146 | 0.98 | MAPT (1.00) | MAPTADRB2KDM4ETDP1ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551454-B2 | Isoproterenol compositions and methods | PH HEALTH LIMITED (IE) | 2026-02-17 | — | — | US | disclosed |
| EP-4687942-A1 | DPP3 INHIBITOR FOR MYOCARDIAL PROTECTION AND PREVENTION OF MYOCARDIAL INJURY IN CRITICALLY ILL PATIENTS WITH BLOOD PRESSURE DECLINE | 4TEEN4 Pharmaceuticals GmbH (DE) | 2026-02-11 | — | — | EP | disclosed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260028423-A1 | PREDICTION OF AN INCREASE OF DPP3 IN A PATIENT WITH SEPTIC SHOCK | 4TEEN4 Pharmaceuticals GmbH (DE) | 2026-01-29 | — | — | US | disclosed |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | PROCTER & GAMBLE (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4633659-A1 | DPP3 INHIBITOR FOR IMPROVEMENT OF PULMONARY FUNCTION IN CRITICALLY ILL PATIENTS | 4TEEN4 Pharmaceuticals GmbH (DE) | 2025-10-22 | — | — | EP | disclosed |
| EP-4021571-B1 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR TREATMENT OF SHOCK | 4TEEN4 Pharmaceuticals GmbH (DE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4562430-A1 | PREDICTION OF AN INCREASE OF DPP3 IN A PATIENT WITH SEPTIC SHOCK | 4TEEN4 Pharmaceuticals GmbH (DE) | 2025-06-04 | — | — | EP | disclosed |
| EP-4552649-A2 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR TREATMENT OF SHOCK | 4TEEN4 Pharmaceuticals GmbH (DE) | 2025-05-14 | — | — | EP | disclosed |
| CN-119630969-A | DPP3 increase in patients predicted to suffer from septic shock | 4TEEN4制药有限公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2017156455-A1 | SYSTEM FOR MAGNETIC DETECTION OF MYOCARDIAL FORCES | UNIVERSITY OF WASHINGTON (US) | 2017-09-14 | — | — | WO | disclosed |
| US-20150157626-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | NEOVACS S.A. (FR) | 2015-06-11 | — | — | US | disclosed |
| US-8992891-B2 | Therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2015-03-31 | — | — | US | disclosed |
| CN-101883561-B | Novel therapeutic methods for treating CMT and related diseases | PHARNEXT | 2014-07-30 | — | — | CN | disclosed |
| EP-2609916-A1 | New therapeutic approaches for treating CMT and related disorders | Pharnext (FR) | 2013-07-03 | — | — | EP | disclosed |
| EP-2211846-B1 | New therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2013-02-27 | — | — | EP | disclosed |
| US-20100310641-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2010-12-09 | — | — | US | disclosed |
| CN-101883561-A | Novel therapeutic methods for treating CMT and related diseases | PHARNEXT | 2010-11-10 | — | — | CN | disclosed |
| EP-2211846-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | Pharnext (FR) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009068668-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028423-A1 | PREDICTION OF AN INCREASE OF DPP3 IN A PATIENT WITH SEPTIC SHOCK | DPP3, DPP4, DPP7 | ADRB2 2278/4885ADRB1 2003/4885ADRB3 294/4885 |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | ADRB2 1465/4885ADRB1 1454/4885ADRB3 872/4885 |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | SQSTM1, BECN1, CUTA | ADRB2 2163/4885ADRB1 1419/4885ADRB3 1405/4885 |
| US-12551454-B2 | Isoproterenol compositions and methods | ADRB1, ADRA1B, ADRA1A | ADRB2 4/4885ADRB1 1/4885ADRB3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.